OrSense’s primary product is a non-invasive blood glucose monitor, for both continuous and spot measurements. It allows self monitoring of blood glucose levels by people with diabetes. The first generation monitor to enter the market, the NBM-200G, is a non-invasive continuous glucose monitor, focused on patients with demanding need for glycemic control in cases such as brittle, nocturnal, and gestational diabetes. The NBM-200G was tested on over 350 subjects, exhibiting comparable accuracy to invasive solutions, while providing superior ease of use and safety. Furthermore, the NBM-200G enables the identification of glucose trends and the detection of hypo- and hyperglycemia events. In an additional clinical application, the NBM-200G may optimally answer the growing need for tight glycemic control in acute care setting. The NBM-200G is expected to be submitted for regulatory approval during 2007, targeting market entry in late 2008.